AACR 2026

SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca

Molecular Glue Brings New Hope for Patients with BRAF or NRAS-Mutant Melanoma or Other RAS/RAF-driven Malignancies An interview with: Ahmad A Tahini MD PhD, Senior Member, Professor, Director, Departm

Wildfires risk more cancer?

AI “Pathomics Platform” Selects Immunotherapy, Predicts Outcome for Patients with Metastatic Non-Small Cell Lung Cancer  An interview with: Rukhmini Bandyopadhyay MD, Postdoctoral Fellow, The Universi

Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer An interview with: Jonathan Wesley Riess MD, Professor of Medic

Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer An interview with: Marija Balic MD PhD, Chief of Medical Breast Oncology,

Refractory Ovarian Cancer Yields to Claudin 6 Targeted Antibody Drug Conjugate

oral pre-cancer lesions injected with nivolumab prevented progression with little morbidity

New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy An interview with Byoung Chul Cho MD PhD, Thoraci

“Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors” An interview with: Elena Garralda MD PhD, Medical Oncologist, Head, Early Drug Development Unit,